carbamates has been researched along with Hyperglycemia in 37 studies
Hyperglycemia: Abnormally high BLOOD GLUCOSE level.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, body weight, waist circumference, fasting serum levels of insulin and C-peptide were lower and less number of patients experienced hypoglycaemia during treatment with metformin vs." | 5.12 | Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. ( Frandsen, M; Lund, SS; Parving, HH; Pedersen, O; Schalkwijk, CG; Smidt, UM; Stehouwer, CD; Tarnow, L; Vaag, A, 2007) |
| " We compared the effects of two insulin secretagogues, repaglinide and glyburide, known to have different efficacy on postprandial hyperglycemia, on carotid intima-media thickness (CIMT) and markers of systemic vascular inflammation in type 2 diabetic patients." | 5.11 | Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. ( Esposito, K; Giugliano, D; Marfella, R; Nappo, F, 2004) |
| " Four trials (200 participants) are included: one short-term single-center trial (n = 7) comparing insulin with oral repaglinide and no medication in people with cystic fibrosis-related diabetes and normal fasting glucose; one long-term multicenter trial (n = 100, 74 of whom had cystic fibrosis-related diabetes) comparing insulin with oral repaglinide and placebo; one long-term multicenter trial (n = 73) comparing insulin with oral repaglinide; and one 12-week single-center trial (n = 20) comparing the long-acting insulin glargine to short-term neutral protamine Hagedorn insulin." | 4.93 | Insulin and oral agents for managing cystic fibrosis-related diabetes. ( Onady, GM; Stolfi, A, 2016) |
| " We fed albino rats a high-fat fructose diet (HFFD) for 2 months to induce insulin resistance/type 2 diabetes and then treated the rats with ellagic acid (10 mg/kg body weight, orally) and/or repaglinide (0." | 3.85 | Estimation of ellagic acid and/or repaglinide effects on insulin signaling, oxidative stress, and inflammatory mediators of liver, pancreas, adipose tissue, and brain in insulin resistant/type 2 diabetic rats. ( Amin, MM; Arbid, MS, 2017) |
| "Both repaglinide and metformin were effective in glycaemic control in new onset patients with type 2 diabetes in China." | 2.79 | Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China. ( Liao, Y; Liu, LY; Liu, W; Ma, J; Tao, T; Wu, PH, 2014) |
| "Repaglinide was also associated with an increase in the AUC(60) and AUC(120) for insulin (+56%, +61%) and C-peptide (+41%, +36%)." | 2.76 | Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. ( Bain, SC; Bodvarsdottir, TB; Bracken, RM; Deacon, CF; Dunseath, G; Holst, JJ; Lowe, GD; Luzio, S; Prior, SL; Rumley, A; Stephens, JW; Wareham, K, 2011) |
| "A total of 16 Caucasian men with type 2 diabetes participated in two placebo-controlled double-blind randomized cross-over studies." | 2.69 | Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. ( Bayer, T; Ismail, I; Luzio, SD; Owens, DR, 2000) |
| "Nateglinide is an amino acid derivative." | 2.41 | Insulin secretagogues. ( Davies, MJ, 2002) |
| "Type 2 diabetes is characterised by a progressive deterioration of the prandial insulin response, in a situation of continuing insulin resistance." | 2.41 | The importance of early insulin secretion and its impact on glycaemic regulation. ( Garber, AJ, 2000) |
| "Repaglinide has few contraindications or drug interactions and can be used in a wide range of patients." | 2.41 | Repaglinide: prandial glucose regulation in clinical practice. ( McDougall, A; Owens, DR, 2000) |
| "In pioglitazone-treated animals, AA and TAS increased above control values while GSH and PCG were normalized." | 1.38 | Oxidative/nitrosative stress and protein damages in aqueous humor of hyperglycemic rabbits: effects of two oral antidiabetics, pioglitazone and repaglinide. ( Gumieniczek, A; Owczarek, B; Pawlikowska, B, 2012) |
| "Type 2 diabetes mellitus is the consequence of both insulin resistance and impaired insulin secretion." | 1.32 | Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. ( Abrahamson, MJ, 2004) |
| "During type 2 diabetes mellitus, repaglinide is the first fast-acting oral antidiabetic drug able to stimulate endogenous insulin secretion during meal by mimicking physiological insulin secretion pattern." | 1.30 | [Mechanisms of action of repaglinide at a cellular level]. ( Thomsen, MK, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (16.22) | 18.7374 |
| 1990's | 4 (10.81) | 18.2507 |
| 2000's | 15 (40.54) | 29.6817 |
| 2010's | 10 (27.03) | 24.3611 |
| 2020's | 2 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Pishdad, R | 1 |
| Pishdad, P | 1 |
| Pishdad, GR | 1 |
| Onady, GM | 2 |
| Stolfi, A | 2 |
| Tanaka, K | 1 |
| Okada, Y | 1 |
| Mori, H | 1 |
| Torimoto, K | 1 |
| Arao, T | 1 |
| Tanaka, Y | 1 |
| Abo-Elseoud, WS | 1 |
| Hassan, ML | 1 |
| Sabaa, MW | 1 |
| Basha, M | 1 |
| Hassan, EA | 1 |
| Fadel, SM | 1 |
| Omori, K | 1 |
| Nomoto, H | 1 |
| Nakamura, A | 1 |
| Takase, T | 1 |
| Cho, KY | 1 |
| Ono, K | 1 |
| Manda, N | 1 |
| Kurihara, Y | 1 |
| Aoki, S | 1 |
| Atsumi, T | 1 |
| Miyoshi, H | 1 |
| Ma, J | 1 |
| Liu, LY | 1 |
| Wu, PH | 1 |
| Liao, Y | 1 |
| Tao, T | 1 |
| Liu, W | 1 |
| Amin, MM | 1 |
| Arbid, MS | 1 |
| Gumieniczek, A | 3 |
| Krzywdzińska, M | 1 |
| Nowak, M | 1 |
| Komsta, L | 1 |
| Chehab, MR | 1 |
| Choudhry, PK | 1 |
| Pandey, R | 1 |
| Deshpande, SB | 1 |
| Stephens, JW | 1 |
| Bodvarsdottir, TB | 1 |
| Wareham, K | 1 |
| Prior, SL | 1 |
| Bracken, RM | 1 |
| Lowe, GD | 1 |
| Rumley, A | 1 |
| Dunseath, G | 1 |
| Luzio, S | 1 |
| Deacon, CF | 1 |
| Holst, JJ | 1 |
| Bain, SC | 1 |
| Owczarek, B | 1 |
| Pawlikowska, B | 1 |
| Davies, MJ | 1 |
| Owens, DR | 3 |
| Cozma, LS | 1 |
| Luzio, SD | 2 |
| Vergès, B | 1 |
| Abrahamson, MJ | 1 |
| Esposito, K | 1 |
| Giugliano, D | 1 |
| Nappo, F | 1 |
| Marfella, R | 1 |
| Nan, DN | 1 |
| Hernández, JL | 1 |
| Fernández-Ayala, M | 1 |
| Carrascosa, M | 1 |
| Lund, SS | 1 |
| Tarnow, L | 1 |
| Stehouwer, CD | 1 |
| Schalkwijk, CG | 1 |
| Frandsen, M | 1 |
| Smidt, UM | 1 |
| Pedersen, O | 1 |
| Parving, HH | 1 |
| Vaag, A | 1 |
| Kapoor, JR | 1 |
| Mooradian, AD | 1 |
| Thurman, JE | 1 |
| Thomsen, MK | 1 |
| Ismail, I | 1 |
| Bayer, T | 1 |
| Garber, AJ | 1 |
| McDougall, A | 1 |
| Menon, PS | 1 |
| Shobha, TR | 1 |
| Prakash, O | 1 |
| Schade, DS | 1 |
| Bragg, A | 1 |
| Schein, PS | 1 |
| Alberti, KG | 1 |
| Williamson, DH | 1 |
| Sassine, A | 2 |
| Rechencq, E | 2 |
| Bourgeois, JM | 2 |
| Danielsson, A | 1 |
| Frimpter, GW | 1 |
| Blickens, DA | 1 |
| Riggi, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Randomised Prospective Comparative Multi-centre Intervention Study of Patients With Cystic Fibrosis and Early Diagnosed Diabetes Mellitus[NCT00662714] | Phase 3 | 73 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)[NCT03819790] | Phase 4 | 119 participants (Actual) | Interventional | 2018-10-02 | Completed | ||
| Inhibition of Intestinal Glucose Absorption by the Bioflavonoid Quercetin in the Obese and in Obese Type 2 Diabetics[NCT00065676] | Phase 2 | 24 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
10 reviews available for carbamates and Hyperglycemia
| Article | Year |
|---|---|
Drug treatments for managing cystic fibrosis-related diabetes.
Topics: Administration, Oral; Bias; Blood Glucose; Carbamates; Cystic Fibrosis; Diabetes Mellitus; Fasting; | 2020 |
Insulin and oral agents for managing cystic fibrosis-related diabetes.
Topics: Administration, Oral; Carbamates; Cystic Fibrosis; Diabetes Mellitus; Humans; Hyperglycemia; Hypogly | 2016 |
Insulin secretagogues.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hyp | 2002 |
Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
Topics: Area Under Curve; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Glucose; Humans; Hyperglycem | 2002 |
The impact of prandial glucose regulation in practice.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperglycemia; Hy | 2002 |
Drug therapy of postprandial hyperglycaemia.
Topics: 1-Deoxynojirimycin; Acarbose; Amyloid; Carbamates; Diabetes Mellitus; Enzyme Inhibitors; Glucosamine | 1999 |
The importance of early insulin secretion and its impact on glycaemic regulation.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Humans; Hyp | 2000 |
Repaglinide: prandial glucose regulation in clinical practice.
Topics: Carbamates; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Piperidines; Post | 2000 |
Current understanding regarding the role of repaglinide in post-prandial hyperglycemia.
Topics: Carbamates; Humans; Hyperglycemia; Hypoglycemic Agents; Piperidines; Postprandial Period; Treatment | 2001 |
Aminoacidurias due to inherited disorders of metabolism. 2.
Topics: Acidosis; Alanine; Amino Acid Metabolism, Inborn Errors; Arginase; Arginine; Carbamates; Citrulline; | 1973 |
6 trials available for carbamates and Hyperglycemia
| Article | Year |
|---|---|
Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea.
Topics: Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; F | 2019 |
Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Topics: Body Mass Index; Carbamates; China; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diab | 2014 |
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
Topics: Adult; Aged; Analysis of Variance; Biomarkers; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; | 2011 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Carotid Artery Diseases; Cross-Sectional Studies | 2004 |
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial.
Topics: Adiponectin; Biomarkers; Blood Glucose; Body Weight; C-Peptide; C-Reactive Protein; Carbamates; Cros | 2007 |
Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
Topics: Administration, Oral; Area Under Curve; Blood Glucose; C-Peptide; Carbamates; Cohort Studies; Cross- | 2000 |
21 other studies available for carbamates and Hyperglycemia
| Article | Year |
|---|---|
Acarbose versus Repaglinide in Diabetes Treatment: A New Appraisal of Two Old Rivals.
Topics: Acarbose; Adult; Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Humans; Hypergl | 2020 |
The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy.
Topics: Aged; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Female; Graves Ophthalmopathy; Humans; H | 2018 |
Chitosan nanoparticles/cellulose nanocrystals nanocomposites as a carrier system for the controlled release of repaglinide.
Topics: Carbamates; Cellulose; Chitosan; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; | 2018 |
Estimation of ellagic acid and/or repaglinide effects on insulin signaling, oxidative stress, and inflammatory mediators of liver, pancreas, adipose tissue, and brain in insulin resistant/type 2 diabetic rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers; Brain; Carbamates; Diabetes Melli | 2017 |
Modulation of nitrosative/oxidative stress in the lung of hyperglycemic rabbits by two antidiabetics, pioglitazone and repaglinide.
Topics: Administration, Oral; Animals; Blood Glucose; Carbamates; Catalase; Diabetes Mellitus, Experimental; | 2009 |
Effects of two oral antidiabetics, pioglitazone and repaglinide, on aconitase inactivation, inflammation and oxidative/nitrosative stress in tissues under alloxan-induced hyperglycemia.
Topics: Aconitate Hydratase; Administration, Oral; Alloxan; Animals; Blood Glucose; Body Weight; Carbamates; | 2011 |
2-Deoxy-D-glucose reverses the Indian red scorpion venom-induced cardiopulmonary abnormalities in anesthetized rats.
Topics: Anesthesia; Animals; Blood Glucose; Carbamates; Cardiovascular Abnormalities; Deoxyglucose; Hypergly | 2011 |
Oxidative/nitrosative stress and protein damages in aqueous humor of hyperglycemic rabbits: effects of two oral antidiabetics, pioglitazone and repaglinide.
Topics: Animals; Antioxidants; Aqueous Humor; Carbamates; Diabetes Mellitus, Experimental; Glutathione Perox | 2012 |
Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context.
Topics: Antihypertensive Agents; Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Diabetes Mellitus | 2004 |
Acute hepatotoxicity caused by repaglinide.
Topics: Aged; Carbamates; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypergl | 2004 |
Postprandial hyperglycemia: are all sulfonylureas created equal?
Topics: Carbamates; Cyclohexanes; Glipizide; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Na | 2008 |
[Mechanisms of action of repaglinide at a cellular level].
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Inulin; Piperidin | 1999 |
Metabolic profile of protease inhibitors studied.
Topics: Adipose Tissue; Animals; Carbamates; Disease Models, Animal; Furans; HIV Protease Inhibitors; Humans | 1999 |
Glycosuria in organophosphate and carbamate poisoning.
Topics: Adult; Carbamates; Female; Glycosuria; Herbicides; Humans; Hyperglycemia; Insecticides; Kidney Tubul | 2000 |
Repaglinide dose response? A clinician's viewpoint.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Exercise; Hu | 1999 |
Insulinotropic meglitinide analogues.
Topics: Carbamates; Humans; Hyperglycemia; Hypoglycemic Agents; Piperidines | 2002 |
Effects of streptozotocin on carbohydrate and lipid metabolism in the rat.
Topics: Acetoacetates; Animals; Antibiotics, Antineoplastic; Blood Glucose; Carbamates; Diabetes Mellitus; D | 1971 |
[Effects of 2 methyl-2- (1 methyl propyl) 1-3 propanediol dicarbamate and (alpha bromo-alpha-ethyl butyryl) urea on glycemia of rabbits].
Topics: Animals; Blood Glucose; Carbamates; Hyperglycemia; Rabbits; Urea | 1969 |
Techniques for measuring amylase secretion from pieces of mouse pancreas.
Topics: Amylases; Animals; Carbamates; Cholecystokinin; Choline; Dinitrophenols; Epinephrine; Evaluation Stu | 1974 |
[Effect of 2 ethyl-3 propyl-glycinamide on blood sugar in rabbits].
Topics: Amides; Animals; Blood Glucose; Carbamates; Ethers, Cyclic; Hyperglycemia; Rabbits; Tranquilizing Ag | 1970 |
Carbohydrate metabolism in normal and hyperglycemic animals treated with 1-methyl-4-(3-methyl-5-isoxazolyl)pyridinium chloride and phenformin.
Topics: Animals; Blood Glucose; Carbamates; Carbohydrate Metabolism; Diabetes Mellitus; Diabetes Mellitus, E | 1971 |